



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/826,463	04/05/2001	Nobuto Yamamoto	Y1004/20017	2419

3000 7590 03/17/2004
CAESAR, RIVISE, BERNSTEIN,
COHEN & POKOTILOW, LTD.
12TH FLOOR, SEVEN PENN CENTER
1635 MARKET STREET
PHILADELPHIA, PA 19103-2212

EXAMINER

ROMEO, DAVID S

ART UNIT PAPER NUMBER

1647

DATE MAILED: 03/17/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/826,463

Applicant(s)

YAMAMOTO, NOBUTO

Examiner

David S Romeo

Art Unit

1647

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 17 November 2003.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 22 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 22 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 06 October 2003 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____.
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____.

DETAILED ACTION

The amendment filed 11/17/2003 has been entered. Claim 22 is pending and being examined.

5 **Maintained Formal Matters, Objections, and/or Rejections:**

The application is not fully in compliance with the sequence rules, 37 C.F.R. § 1.821-1.825. Applicant argues that a nucleotide has been removed from Figure 6 so that it complies with this rule. Applicant's arguments have been fully considered but they are not persuasive. Figure 6 contains nucleic acid sequence(s) with 10 or more nucleotides,
10 at least 4 of which are specifically defined.

New Formal Matters, Objections, and/or Rejections:

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all
15 obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains.
20 Patentability shall not be negated by the manner in which the invention was made.

Claim 22 is rejected under 35 U.S.C. 103(a) as being unpatentable over
Yamamoto (A) (U. S. Patent No. 5,177,002) in view of Cooke (U) (J Clin Invest. 1985
Dec;76(6):2420-4), Quirk (U) (Biotechnol Appl Biochem. 1989 Jun;11(3):273-87),
25 Lichenstein (A) (U. S. Patent No. 5,652,352), Murphy (B) (U. S. Patent No. 5,516,657),
and Luckow (V).

Yamamoto teaches a process of converting glycosylated Gc protein (Gc1 isoform) to a highly potent macrophage activating factor (GcMAF) by contacting Gc protein with immobilized β -galactosidase and sialidase (Example 2, columns 9-10; paragraph bridging columns 2-3; column 4, full paragraph 2; paragraph bridging columns 4-5). The innermost sugar of the oligosaccharide moiety of Gc1 protein is N-acetylgalactosamine. Treatment of Gc1 protein with endo-N-acetylglucosaminidase, which results in the cleavage of the N-acetylgalactosamine, results in a molecule which cannot be then converted to macrophage activating factor (column 5, full paragraph 1). The macrophage activating factor is believed to comprise a protein in substantially pure form having substantially the amino acid sequence of human group specific component, and a terminal O-linked N-acetylgalactosamine group (column 5, full paragraph 3). The Gc protein has a molecular weight of about 52,000 (sentence bridging columns 1-2) and comprises approximately 458 amino acids, as indicated in Figures 1 and 2. The Gc protein has a molecular weight of about 52,000, comprises approximately 458 amino acids, and has three distinct domains, as evidenced by Cooke (Figure 3; page 2423, paragraph bridging left and right columns).

The Gc protein is purified from human blood (column 5, full paragraph 5).

The Gc protein is also known as "vitamin-D binding protein" (paragraph bridging columns 1-2). Yamamoto refers to Cooke for nucleotide and amino acid sequences of Gc protein (paragraph bridging columns 1-2).

Yamamoto does not teach, in the sense that Yamamoto does not anticipate, Gc protein obtained via recombinant DNA technology and its conversion to GcMAF.

Art Unit: 1647

The concern about human viral contamination in products purified from blood may be avoided if these products are obtained via recombinant DNA technology. See Quirk, page 273, last full paragraph. Material derived from *E. coli* may present the problem of co-purification of LPS which has endotoxin activity. See Quirk, paragraph
5 bridging pages 273-274.

Cooke discloses a cDNA encoding the human vitamin D-binding protein (hDBP) and its nucleotide and amino acid sequence (page 2421, Figure 2). Comparison of the sequence of the hDBP mRNA and protein to existing protein and nucleic acid data banks demonstrates a strong and highly characteristic homology of the hDBP with human
10 albumin (hALB) and human alpha-fetoprotein (hAFP). Based upon this structural comparison, Cooke establishes that DBP is a member of the ALB and AFP gene family. See the Abstract. Cooke's sequence represents the Gc1 allele (page 2424, left column).

Lichenstein discloses that the human serum proteins albumin (ALB), α -feta-protein (AFP) and vitamin D binding protein (VDB) are known to be members of a
15 multigene ALB family. All three proteins are found in serum. See column 1, lines 10-15. Lichenstein discloses human afamin (AFM). It shares strong similarity to albumin family members and has the characteristic pattern of disulfide bonds observed in this family. In addition, the gene maps to chromosome 4 as do other members of the albumin gene family. Thus, AFM is the fourth member of the albumin family of proteins. AFM
20 cDNA was stably transfected into Chinese hamster ovary cells and recombinant protein (rAFM) was purified from conditioned medium. column 1, lines 45-65. Host cells from mammals, prokaryotes, fungi, yeast, insects and the like are used for the recombinant expression of AFM (column 13, lines 52-55).

Murphy provides Baculovirus vectors to express recombinant proteins during Baculovirus infection. One advantage of the Baculovirus vectors over bacterial and yeast expression vectors includes the expression of recombinant proteins that are essentially authentic and are antigenically and/or biologically active. In addition, Baculoviruses are not pathogenic to vertebrates or plants and do not employ transformed cells or transforming elements as do the mammalian expression systems. Although mammalian expression systems result in the production of fully modified, functional protein, yields are often low. E. coli systems result in high yields of recombinant protein but the protein is not modified and may be difficult to purify in a nondenatured state. See column 1, lines 40-52. The list of foreign genes that may be inserted into the Baculovirus vectors includes human blood factors (column 6, full paragraph 3).

Luckow discloses that baculovirus vectors have become widely used to direct the expression of foreign genes. The recombinant proteins are antigenically, immunogenically, and functionally similar to their authentic counterparts (page 51, full paragraph 1). Luckow discloses recombinant baculoviruses and baculovirus vectors (pages 55-66). Luckow discloses that O-linked glycosylation is known to occur on foreign proteins expressed in insect cells (page 74, full paragraphs 2-3). Expression of foreign genes by baculovirus vectors is an enabling technology that permits the production of proteins that cannot often be achieved with other expression systems (page 83, last full paragraph).

Cooke, Quirk, Lichenstein, Murphy, and Luckow do not teach, in the sense that Cooke, Quirk, Lichenstein, Murphy, and Luckow do not anticipate, Gc protein obtained via recombinant DNA technology and its conversion to GcMAF.

However, it would have been obvious to one of ordinary skill in the art at the time of Applicants' invention to purify a Gc1 isoform from blood, contact the purified Gc1 isoform in vitro with immobilized β -galactosidase and sialidase, and obtain GcMAF, as taught by Yamamoto, and to modify that teaching by obtaining the Gc protein via

5 recombinant DNA technology, i.e., cloning a Gc1 isoform into a baculovirus vector and expressing the cloned Gc1 isoform, using the teachings of Cooke, Quirk, Lichenstein, Murphy, and Luckow, with a reasonable expectation of success.

One of ordinary skill in the art would be motivated to make this modification because the concern about human viral contamination in products purified from blood

10 may be avoided if these products are obtained via recombinant DNA technology, material derived from E. coli may present the problem of co-purification of LPS which has endotoxin activity, E. coli systems result in high yields of recombinant protein but the protein is not modified and may be difficult to purify in a nondenatured state, Gc protein (vitamin D binding protein) is a ALB family member, host cells from insects can used for

15 the recombinant expression of an ALB family member, foreign genes for human blood factors may be inserted into Baculovirus vectors, one advantage of the Baculovirus vectors over bacterial and yeast expression vectors includes the expression of recombinant proteins that are essentially authentic and are antigenically and/or biologically active, Baculoviruses are not pathogenic to vertebrates or plants and do not

20 employ transformed cells or transforming elements as do the mammalian expression systems, although mammalian expression systems result in the production of fully modified, functional protein, yields are often low, recombinant proteins expressed in baculovirus systems are antigenically, immunogenically, and functionally similar to their

authentic counterparts, O-linked glycosylation is known to occur on foreign proteins expressed in insect cells, and expression of foreign genes by baculovirus vectors is an enabling technology that permits the production of proteins that cannot often be achieved with other expression systems. The invention is prima facie obvious over the prior art.

5

Applicant argues that the obviousness rejection brought forth on claims with a scope similar to the present claims is no longer valid. Applicant's arguments have been fully considered but they are not persuasive. The examiner believes Applicant is referring to the statement in the last Office action that claims "of a scope similar to the present claims were rejected under 35 U.S.C. 103(a) in Applicant's predecessor application U.S. application serial no. 08/618,485 and that rejection was affirmed after appeal before the board of patent appeals and interferences" (page 6 of the last Office action). The examiner believes that this argument is not germane to the present rejection because the examiner does not rely upon the rejection under 35 U.S.C. 103(a) in Applicant's predecessor application (U.S. application serial no. 08/618,485) for the present rejection.

Conclusion

Claim 22 is not allowable.

20

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

Art Unit: 1647

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

ANY INQUIRY CONCERNING THIS COMMUNICATION OR EARLIER COMMUNICATIONS FROM THE EXAMINER SHOULD BE DIRECTED TO DAVID S. ROMEO WHOSE TELEPHONE NUMBER IS (571) 272-0890. THE EXAMINER CAN NORMALLY BE REACHED ON MONDAY THROUGH FRIDAY FROM 7:30 A.M. TO 4:00 P.M. IF ATTEMPTS TO REACH THE EXAMINER BY TELEPHONE ARE UNSUCCESSFUL, THE EXAMINER'S SUPERVISOR, GARY KUNZ, CAN BE REACHED ON (571) 272-0887.

IF SUBMITTING OFFICIAL CORRESPONDENCE BY FAX, APPLICANTS ARE ENCOURAGED TO SUBMIT OFFICIAL CORRESPONDENCE TO THE FOLLOWING TC 1600 BEFORE AND AFTER FINAL RIGHTFAX NUMBERS:

BEFORE FINAL (703) 872-9306
AFTER FINAL (703) 872-9307

CUSTOMERS ARE ALSO ADVISED TO USE CERTIFICATE OF FACSIMILE PROCEDURES WHEN SUBMITTING A REPLY TO A NON-FINAL OR FINAL OFFICE ACTION BY FACSIMILE (SEE 37 CFR 1.6 AND 1.8).

FAXED DRAFT OR INFORMAL COMMUNICATIONS SHOULD BE DIRECTED TO THE EXAMINER AT (571) 273-0890.

ANY INQUIRY OF A GENERAL NATURE OR RELATING TO THE STATUS OF THIS APPLICATION OR PROCEEDING SHOULD BE DIRECTED TO THE GROUP RECEPTIONIST WHOSE TELEPHONE NUMBER IS (703) 308-0196.



DAVID ROMEO
PRIMARY EXAMINER
ART UNIT 1647

DSR
MARCH 5, 2004